[HTML][HTML] Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 …
Background Melanoma brain metastases (MBMs) are a challenging clinical problem with
high morbidity and mortality. Although first-line dabrafenib–trametinib and ipilimumab …
high morbidity and mortality. Although first-line dabrafenib–trametinib and ipilimumab …
[HTML][HTML] Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 …
PKH Lau, B Feran, L Smith, A Lasocki… - … for ImmunoTherapy of …, 2021 - jitc.bmj.com
Background Melanoma brain metastases (MBMs) are a challenging clinical problem with
high morbidity and mortality. Although first-line dabrafenib–trametinib and ipilimumab …
high morbidity and mortality. Although first-line dabrafenib–trametinib and ipilimumab …
Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 …
PKH Lau, B Feran, L Smith, A Lasocki… - Journal for …, 2021 - research.monash.edu
Background Melanoma brain metastases (MBMs) are a challenging clinical problem with
high morbidity and mortality. Although first-line dabrafenib-trametinib and ipilimumab …
high morbidity and mortality. Although first-line dabrafenib-trametinib and ipilimumab …
Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 …
PKH Lau, B Feran, L Smith, A Lasocki… - … for Immunotherapy of …, 2021 - europepmc.org
Background Melanoma brain metastases (MBMs) are a challenging clinical problem with
high morbidity and mortality. Although first-line dabrafenib-trametinib and ipilimumab …
high morbidity and mortality. Although first-line dabrafenib-trametinib and ipilimumab …
Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 …
PKH Lau, B Feran, L Smith… - Journal for …, 2021 - research-repository.uwa.edu.au
Background Melanoma brain metastases (MBMs) are a challenging clinical problem with
high morbidity and mortality. Although first-line dabrafenib-trametinib and ipilimumab …
high morbidity and mortality. Although first-line dabrafenib-trametinib and ipilimumab …
Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 …
PKH Lau, B Feran, L Smith, A Lasocki… - Journal for …, 2021 - search.proquest.com
Background Melanoma brain metastases (MBMs) are a challenging clinical problem with
high morbidity and mortality. Although first-line dabrafenib–trametinib and ipilimumab …
high morbidity and mortality. Although first-line dabrafenib–trametinib and ipilimumab …
Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 …
PKH Lau, B Feran, L Smith, A Lasocki… - … for ImmunoTherapy of …, 2021 - profiles.wustl.edu
Background Melanoma brain metastases (MBMs) are a challenging clinical problem with
high morbidity and mortality. Although first-line dabrafenib-trametinib and ipilimumab …
high morbidity and mortality. Although first-line dabrafenib-trametinib and ipilimumab …
Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 …
PKH Lau, B Feran, L Smith… - Journal for …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Melanoma brain metastases (MBMs) are a challenging clinical problem with
high morbidity and mortality. Although first-line dabrafenib-trametinib and ipilimumab …
high morbidity and mortality. Although first-line dabrafenib-trametinib and ipilimumab …
Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 …
PKH Lau, B Feran, L Smith, A Lasocki… - … for Immunotherapy of …, 2021 - europepmc.org
Background Melanoma brain metastases (MBMs) are a challenging clinical problem with
high morbidity and mortality. Although first-line dabrafenib-trametinib and ipilimumab …
high morbidity and mortality. Although first-line dabrafenib-trametinib and ipilimumab …